Oropharyngeal carcinoma
diseaseOn this page
Also known as cancer of oropharynxcancer of the oropharynxcarcinoma of oropharynxcarcinoma of the oropharynxoropharyngeal canceroropharyngeal throat canceroropharynx carcinoma
Summary
Oropharyngeal carcinoma (MONDO:0044926) is a cancer (an umbrella term covering 6 Mondo subtypes) and 135 clinical trials. Top therapeutic interventions include cisplatin, alpelisib, and diphenhydramine. A subtype of head and neck carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Umbrella term: 6 Mondo subtypes
- Clinical trials: 135
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | oropharyngeal carcinoma |
| Mondo ID | MONDO:0044926 |
| NCIT | C9105 |
| UMLS | C2349952 |
| MedGen | 379086 |
| GARD | 0027983 |
| Anatomy (UBERON) | UBERON:0001729 |
| Is cancer (heuristic) | yes |
Also known as: cancer of oropharynx · cancer of the oropharynx · carcinoma of oropharynx · carcinoma of the oropharynx · oropharyngeal cancer · oropharyngeal carcinoma · oropharyngeal throat cancer · oropharynx carcinoma
Disease family
This is a subtype of head and neck carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › head and neck carcinoma › oropharyngeal carcinoma
Related subtypes (15): eye carcinoma, external ear carcinoma, middle ear carcinoma, nasal cavity carcinoma, growth hormone-producing pituitary gland carcinoma, hypopharyngeal carcinoma, ameloblastic carcinoma, laryngeal small cell carcinoma, pharyngeal adenoid cystic carcinoma, head and neck squamous cell carcinoma, nasopharyngeal carcinoma, pituitary adenocarcinoma, carcinoma of floor of mouth, lip and oral cavity carcinoma, nasal cavity and paranasal sinus carcinoma
Subtypes (6): epiglottis cancer, carcinoma in situ of oropharynx, adenoid cystic carcinoma of oropharynx, carcinoma of soft palate, tonsil carcinoma, oropharynx squamous cell carcinoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 135.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 72 |
| PHASE2 | 35 |
| PHASE1/PHASE2 | 10 |
| PHASE1 | 10 |
| PHASE3 | 6 |
| PHASE4 | 1 |
| PHASE2/PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT03691441 | PHASE4 | UNKNOWN | Comparative Effectiveness Trial of Transoral Head and Neck Surgery Followed by Adjuvant Radio(Chemo)Therapy Versus Primary Radiochemotherapy for Oropharyngeal Cancer |
| NCT04019548 | PHASE3 | RECRUITING | Assessment of Swallowing Function and Quality of Life in Oropharyngeal Cancer Patients Treated by Chemo-radiotherapy |
| NCT04116047 | PHASE3 | ACTIVE_NOT_RECRUITING | CompARE: Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer (OPC) |
| NCT05451004 | PHASE3 | RECRUITING | SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal Cancer |
| NCT07402538 | PHASE3 | NOT_YET_RECRUITING | Surgery With or Without Neoadjuvant Treatment of SBRT Plus Chemoimmunotherapy in Resectable Locally Advanced Oral and HPV-unrelated Oropharyngeal Squamous Cell Carcinoma |
| NCT00964977 | PHASE3 | COMPLETED | Effectiveness of Adjuvant Radiotherapy in Small Oropharyngeal Squamous Cell Cancer and Single Lymph Node Metastasis. |
| NCT01434394 | PHASE2/PHASE3 | COMPLETED | Neoadjuvant Erbitux Based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer |
| NCT04189107 | PHASE3 | COMPLETED | Postoperative Pain, Why Still in Hospital and DAOH Following TORS for SCCUP & OSAS |
| NCT03215719 | PHASE2 | RECRUITING | Adaptive Treatment De-escalation in Favorable Risk HPV-Positive Oropharyngeal Carcinoma |
| NCT03224000 | PHASE2 | ACTIVE_NOT_RECRUITING | Trial of Magnetic Resonance Imaging Guided Radiotherapy Dose Adaptation in Human Papilloma Virus Positive Oropharyngeal Cancer |
| NCT03383094 | PHASE2 | ACTIVE_NOT_RECRUITING | Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer |
| NCT03822897 | PHASE2 | ACTIVE_NOT_RECRUITING | De-Escalation Radiotherapy in Patients With Low-Risk HPV-Related Oropharyngeal Squamous Cell Carcinoma |
| NCT04151082 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | High Dose Steroid Therapy (Prednisone or Methylprednisolone) for the Improvement of Symptoms of Late Radiation-Associated Lower Cranial Neuropathy in Oropharyngeal Cancer Survivors |
| NCT04287868 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies |
| NCT04432597 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers |
| NCT04708470 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers |
| NCT05075980 | PHASE2 | ACTIVE_NOT_RECRUITING | Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study |
| NCT05232851 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | A Vaccine (PDS0101) Alone or in Combination With Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx Cancer |
| NCT05491512 | PHASE2 | RECRUITING | A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer |
| NCT05799144 | PHASE2 | RECRUITING | pBI-11 & TA-HPV (With Pembrolizumab as Treatment for Patients w/Advanced, PD-L1 CPS≥1, hrHPV+ Oropharyngeal Cancer |
| NCT05894083 | PHASE2 | RECRUITING | A Phase II Study for p16+ Oropharyngeal Cancer PerSonalized De-escalation Treatment at University of MIchigan (CuSToMIze) |
| NCT06445114 | PHASE2 | RECRUITING | Using CircuLating Tumor DNA to Risk Adapt Post-Operative Therapy for HPV-associated Oropharyngeal Cancer |
| NCT06984861 | PHASE2 | RECRUITING | A Study of Reduced Radiation Therapy With Chemotherapy in People With HPV-Positive Throat Cancer |
| NCT06997068 | PHASE2 | RECRUITING | Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Head and Neck Cancer in a Rural Midwest United States Population |
| NCT07209189 | PHASE2 | RECRUITING | Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN) |
| NCT07290621 | PHASE2 | RECRUITING | Toripalimab in Combination With Standard Treatment for Human Papillomavirus (HPV) Positive Throat Cancer |
| NCT07418034 | PHASE2 | NOT_YET_RECRUITING | A Single Arm Phase II Trial in p16-positive Oropharynx Cancer of Selective Dose De-escalation of nodAl VolumEs at Minimal Risk and Primary Site Disease (SAVED) |
| NCT00064103 | PHASE1/PHASE2 | COMPLETED | Gene Therapy in Preventing Cancer in Patients With Premalignant Carcinoma of the Oral Cavity or Pharynx |
| NCT00330382 | PHASE2 | COMPLETED | Bowman-Birk Inhibitor Concentrate in Preventing Cancer in Patients With Oral Leukoplakia |
| NCT00780312 | PHASE2 | COMPLETED | Physiotherapy Treatment for Patients Suffering From Head and Neck Cancer |
| NCT01032928 | PHASE2 | COMPLETED | Respiratory-Swallow Training in Veterans With Oropharyngeal Cancer |
| NCT01435252 | PHASE2 | COMPLETED | A Phase II Study In Patients With Advanced Head And Neck Cancer Of Standard Chemoradiation And Add-On Cetuximab |
| NCT01440270 | PHASE2 | COMPLETED | Neo-adjuvant Erbitux-based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer |
| NCT01516996 | PHASE2 | UNKNOWN | Safety and Efficacy Study of Nimotuzumab Plus Neoadjuvant and Concurrent Chemoradiotherapy to Treat Oropharynx and Hypopharynx Cancer |
| NCT01585428 | PHASE2 | COMPLETED | Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers |
| NCT01695122 | PHASE2 | COMPLETED | Valproic Acid and Platinum-based Chemoradiation in Locally Advanced Head and Neck Squamous Cell Carcinoma |
| NCT01711541 | PHASE1/PHASE2 | COMPLETED | Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck Cancer |
| NCT01733797 | PHASE2 | COMPLETED | Trismus Trial of Therabite vs Wooden Spatula in Head and Neck Cancer Patients |
| NCT01806675 | PHASE1/PHASE2 | COMPLETED | 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy |
| NCT02159703 | PHASE2 | COMPLETED | A Single-arm Phase II Study of Post-Transoral Robotic Surgery (TORS) Alone to the Primary Tumor Site and Selective Neck Dissection (SND) Followed by Adjuvant Radiation Therapy (+/- Chemotherapy) to the Regional Nodes for Advanced Stage, Human Papilloma Virus (HPV) Positive, Oropharyngeal Cancer |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| CISPLATIN | 4 | 12 |
| ALPELISIB | 4 | 1 |
| DIPHENHYDRAMINE | 4 | 1 |
| DURVALUMAB | 4 | 1 |
| HYDROXYUREA | 4 | 1 |
| VALPROIC ACID | 4 | 1 |
| BINTRAFUSP ALFA | 3 | 4 |
| VELIPARIB | 3 | 2 |
| BALSTILIMAB | 3 | 1 |
| ENTINOSTAT | 3 | 1 |
| FICLATUZUMAB | 3 | 1 |
| NIMOTUZUMAB | 3 | 1 |
| UTOMILUMAB | 3 | 1 |
| CONTUSUGENE LADENOVEC | 2 | 1 |
| IMMUNOCYTOKINE NHS-IL12 | 2 | 1 |
| PEXIPEPIMUT-S | 2 | 1 |
| LONTUCIREV (REPLICATING ADENOVIRUS) | 1 | 1 |
| PELTOPEPIMUT-S | 1 | 1 |